Computer‐Aided Discovery of Potent Broad‐Spectrum Vaccine Adjuvants
Authors:
Open Access
- 23 March 2023
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (18) , e202301059
Abstract
Adjuvants stimulate the immune system to vigorously respond to a vaccine. While current adjuvants such as aluminum salts and oil‐in‐water emulsions have been used for decades, they do not generate broad and long‐lasting responses in many vaccines. Consequently, more potent adjuvants are needed. Here, using computer‐aided molecule design and machine learning, we discovered 2 new, broad‐spectrum adjuvants that can boost vaccine responses. Our library containing 46 toll‐like receptor (TLR)‐targeting agonist ligands were assembled on Au nanoparticles. Comprehensive in vitro, ex vivo and in vivo studies showed both leads promoted dendritic cell activation via multiple TLRs and enhanced antigen presentation to T cells. When used together with tumor‐specific antigens to immunize mice against B16‐OVA melanoma and 4T1‐PD1 breast cancer, both adjuvants unleashed strong immune responses that suppressed tumor growth and lung metastases. Our results show computer‐aided design and screening can rapidly uncover potent adjuvants for tackling waning immunity in current vaccines.Keywords
Funding Information
- National Natural Science Foundation of China (22076210, 22150006, 21920102007, 22021003, 22036002, 92043301)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2022042)
- National Key Research and Development Program of China (2018YFA0901101, 2021YFE0101500)
This publication has 70 references indexed in Scilit:
- The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6Veterinary Research, 2013
- The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggeringImmunobiology, 2013
- Activation of the Inflammasome and Enhanced Migration of Microparticle-Stimulated Dendritic Cells to the Draining Lymph NodeMolecular Pharmaceutics, 2012
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2010
- Vaccine Adjuvants: Putting Innate Immunity to WorkImmunity, 2010
- Peptides conjugated to gold nanoparticles induce macrophage activationMolecular Immunology, 2009
- Phagocytosis and antigen presentation in dendritic cellsImmunological Reviews, 2007
- CD45 negatively regulates tumour necrosis factor and interleukin‐6 production in dendritic cellsImmunology, 2006
- Binding Affinities of Host–Guest, Protein–Ligand, and Protein–Transition‐State ComplexesAngewandte Chemie International Edition, 2003
- The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cellsJournal of Allergy and Clinical Immunology, 2003